Helix BioPharma Reports Fiscal Loss, Refocuses Strategy
Company Announcements

Helix BioPharma Reports Fiscal Loss, Refocuses Strategy

Story Highlights

Helix BioPharma (TSE:HBP) has released an update.

Helix BioPharma reported a net loss of $9.26 million for fiscal 2024, driven by its continued investment in the development of its LDOS47 platform for cancer therapies. The company is refocusing its resources on combination therapy for Non-Small Cell Lung Carcinoma and plans to close its Edmonton laboratory by the end of October 2024.

For further insights into TSE:HBP stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskHelix BioPharma Highlights L-DOS47 at World ADC
TipRanks Canadian Auto-Generated NewsdeskHelix BioPharma Announces New Transfer Agent
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App